What’s this? A rival bidder heads back to the table with a better offer for Tetraphase. Antibiotics show faint signs of life
The unlikely bidding war for antibiotic maker Tetraphase isn’t over.
After AcelRx got the auction started with an offer to buy the failed biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
